Abstract | UNLABELLED: METHOD: RESULTS: Ac-GluGlu-CycMSH[ DOTA] displayed 0.6 nM MC1 receptor binding affinity in B16/F1 cells. Ac-GluGlu-CycMSH[ DOTA]-111In was readily prepared with greater than 95% radiolabeling yield. Ac-GluGlu-CycMSH[ DOTA]-111In exhibited high tumor uptake (11.42 +/- 2.20% ID/g 2 h postinjection) and prolonged tumor retention (9.42 +/- 2.41% ID/g 4 h postinjection) in B16/F1 melanoma-bearing C57 mice. The uptake values for nontarget organs were generally low (<1.3% ID/g) except for the kidneys 2, 4, and 24 h postinjection. CONCLUSIONS:
DOTA position exhibited profound effect on melanoma targeting and pharmacokinetic properties of Ac-GluGlu-CycMSH[ DOTA]-111In, providing a new insight into the design of lactam bridge-cyclized peptide for melanoma imaging and therapy.
|
Authors | Haixun Guo, Jianquan Yang, Fabio Gallazzi, Eric R Prossnitz, Larry A Sklar, Yubin Miao |
Journal | Bioconjugate chemistry
(Bioconjug Chem)
Vol. 20
Issue 11
Pg. 2162-8
(Nov 2009)
ISSN: 1520-4812 [Electronic] United States |
PMID | 19817405
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Chelating Agents
- Heterocyclic Compounds, 1-Ring
- Indium Radioisotopes
- Lactams
- Radiopharmaceuticals
- 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
- alpha-MSH
|
Topics |
- Animals
- Chelating Agents
(chemistry)
- Drug Delivery Systems
(methods)
- Drug Design
- Heterocyclic Compounds, 1-Ring
(chemistry)
- Indium Radioisotopes
(chemistry, pharmacokinetics)
- Kidney
(metabolism)
- Lactams
- Melanoma, Experimental
(drug therapy)
- Mice
- Mice, Inbred C57BL
- Pharmacokinetics
- Radiopharmaceuticals
(administration & dosage, chemical synthesis, pharmacokinetics)
- Structure-Activity Relationship
- alpha-MSH
(chemistry, pharmacokinetics)
|